EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Circulating low density neutrophils are associated with resistance to anti‐PD1 immunotherapy in squamous head and neck cancer

Virginia Arrazubi iD, Saioa Goñi iD, Iranzu González-Borja, Irene Hernandez-Garcia, Hugo Arasanz iD, Jairo Pérez-Sanz iD, Ana Isabel Bocanegra iD, Grazyna Kochan iD, David Escors iD, Yerani Ruiz de Azúa, Jesús María Elizalde, Antonio Viúdez iD und 1 weitere

Head & Neck · 2023

DOI: 10.1002/hed.27536 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Head & Neck, 2023. Verfasst von Virginia Arrazubi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Oncobiona Group, Navarrabiomed, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain. Hauptthemen laut MEDLINE: Interleukin-7, Head and Neck Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Sociedad Española de Oncología Médica.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Identification of predictive biomarkers to Immune checkpoint inhibitors (ICIs) in head and neck cancer (HNSCC) is an unmet need.

Methods

This was a prospective observational study including 25 patients with HNSCC treated with immunotherapy or chemotherapy after a prior platinum‐based regimen. Low density neutrophils (LDNs) and serum markers were analyzed.

Results

In the immunotherapy cohort, patients with high LDN levels had a shorter progression free survival (PFS) (1.8 months vs. 10.9 months; * p = 0.034). Also, progressors showed higher percentage of LDNs compared to non‐progressors although significance was not reached (mean 20.68% vs. 4.095%, p = 0.0875). These findings were not replicated in patients treated with chemotherapy. High levels of interleukin‐7 (IL7) were correlated with a significantly longer overall survival (OS) (13.47 months 3.51 vs. months, * p = 0.013).

Conclusions

High baseline circulating LDNs and low IL7 could identify a subset of patients intrinsically refractory to ICIs as monotherapy in HNSCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-7Head and Neck NeoplasmsHumansSquamous Cell Carcinoma of Head and NeckNeutrophilsBiomarkersImmunotherapy

Stichwörter der Autor:innen

biomarkerhead and neck cancer (HNC)immunotherapylow density neutrophils (LDN)predictive

Substanzen

Interleukin-7Biomarkers

Autor:innen und Institutionen

  • Oncobiona Group, Navarrabiomed, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
  • Medical Oncology Department, Hospital Universitario de Navarra, Pamplona, Spain.
  • Oncoimmunology Group, Navarrabiomed, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
  • Pathology Department, Hospital Universitario de Navarra, Pamplona, Spain.

ORCID-Profile: Virginia Arrazubi, Saioa Goñi, Hugo Arasanz, Jairo Pérez-Sanz, Ana Isabel Bocanegra, Grazyna Kochan, David Escors, Antonio Viúdez, Ruth Vera

Förderung

  • Sociedad Española de Oncología Médica

Zitieren

APA

Arrazubi, V., Goñi, S., González-Borja, I., Hernandez-Garcia, I., Arasanz, H., Pérez-Sanz, J., Bocanegra, A. I., Kochan, G., Escors, D., Ruiz de Azúa, Y., Elizalde, J. M., Viúdez, A., & Vera, R. (2023). Circulating low density neutrophils are associated with resistance to anti‐PD1 immunotherapy in squamous head and neck cancer. Head & Neck. https://doi.org/10.1002/hed.27536

Vancouver

Arrazubi V, Goñi S, González-Borja I, Hernandez-Garcia I, Arasanz H, Pérez-Sanz J, et al. Circulating low density neutrophils are associated with resistance to anti‐PD1 immunotherapy in squamous head and neck cancer. Head & Neck. 2023. doi:10.1002/hed.27536

BibTeX
@article{Arrazubi2023,
  author = {Arrazubi, Virginia and Goñi, Saioa and González-Borja, Iranzu and Hernandez-Garcia, Irene and Arasanz, Hugo and Pérez-Sanz, Jairo and Bocanegra, Ana Isabel and Kochan, Grazyna and Escors, David and Ruiz de Azúa, Yerani and Elizalde, Jesús María and Viúdez, Antonio and Vera, Ruth},
  title = {Circulating low density neutrophils are associated with resistance to anti‐PD1 immunotherapy in squamous head and neck cancer},
  journal = {Head & Neck},
  year = {2023},
  doi = {10.1002/hed.27536}
}
Kostenlos starten →